MGH, Dana-Farber Unveil AI Tool Predicting 348 Diseases From 683,000 Health Records
Updated
Updated · The Boston Globe · Jul 15
MGH, Dana-Farber Unveil AI Tool Predicting 348 Diseases From 683,000 Health Records
1 articles · Updated · The Boston Globe · Jul 15
Summary
Nature published results showing Aladynoulli can estimate patients’ risk of 348 diseases from electronic health records and, when available, genetic test data.
683,000 patient records—many from the UK Biobank—were used to train the model, which researchers said outperformed established calculators for 10-year cardiovascular risk and 1-year breast cancer risk.
Colorectal cancer was a standout use case: the system identified 17 related conditions and could flag patients for earlier colonoscopies, potentially catching cancer or precancerous polyps before standard age-based screening.
Researchers said the model improves as patients generate more records across specialties, helping connect clues that individual doctors may miss across departments and over time.
Dana-Farber and Massachusetts General hope to integrate the tool into their health-record systems, but the team gave no timeline and said broader clinical rollout still faces a complex path.
An AI can now predict 348 diseases. Can we trust an algorithm with our lives over a doctor's judgment?
This new AI promises to predict your future illnesses. But could it create a new form of health discrimination?
Aladynoulli’s Breakthrough: Lifetime Risk Prediction for 348 Diseases Revolutionizes Early Intervention
Overview
Aladynoulli, introduced in July 2026, marks a significant leap forward in medical diagnostics by enabling healthcare providers to identify and manage patient risks more effectively. This groundbreaking system forecasts the development of various diseases with remarkable precision, shifting healthcare towards a more proactive and preventative approach. One of its key strengths is the ability to predict colorectal cancer with high accuracy, allowing doctors to flag patients at high risk and intervene early. By offering a new frontier in early intervention, Aladynoulli promises to revolutionize patient care and improve outcomes across multiple diseases.